JP2015127343A5 - - Google Patents

Download PDF

Info

Publication number
JP2015127343A5
JP2015127343A5 JP2015076943A JP2015076943A JP2015127343A5 JP 2015127343 A5 JP2015127343 A5 JP 2015127343A5 JP 2015076943 A JP2015076943 A JP 2015076943A JP 2015076943 A JP2015076943 A JP 2015076943A JP 2015127343 A5 JP2015127343 A5 JP 2015127343A5
Authority
JP
Japan
Prior art keywords
disease
composition
parkinson
condition
huntington
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015076943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015127343A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015127343A publication Critical patent/JP2015127343A/ja
Publication of JP2015127343A5 publication Critical patent/JP2015127343A5/ja
Pending legal-status Critical Current

Links

JP2015076943A 2008-11-14 2015-04-03 変性α−シヌクレイン機能の治療のための組成物および方法 Pending JP2015127343A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19924308P 2008-11-14 2008-11-14
US61/199,243 2008-11-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011536351A Division JP2012508740A (ja) 2008-11-14 2009-09-04 変性α−シヌクレイン機能の治療のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2015127343A JP2015127343A (ja) 2015-07-09
JP2015127343A5 true JP2015127343A5 (enExample) 2015-08-27

Family

ID=42170611

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011536351A Pending JP2012508740A (ja) 2008-11-14 2009-09-04 変性α−シヌクレイン機能の治療のための組成物および方法
JP2015076943A Pending JP2015127343A (ja) 2008-11-14 2015-04-03 変性α−シヌクレイン機能の治療のための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011536351A Pending JP2012508740A (ja) 2008-11-14 2009-09-04 変性α−シヌクレイン機能の治療のための組成物および方法

Country Status (9)

Country Link
US (2) US20120052053A1 (enExample)
EP (1) EP2361089A4 (enExample)
JP (2) JP2012508740A (enExample)
CN (1) CN102245180A (enExample)
AU (1) AU2009314447A1 (enExample)
BR (1) BRPI0920498A2 (enExample)
CA (1) CA2745451A1 (enExample)
GB (1) GB2480159A (enExample)
WO (1) WO2010056413A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2466912B (en) * 2007-11-29 2012-01-04 Hospital For Sick Children Compositions and methods for treating lysosomal disorders
US9265735B2 (en) * 2010-11-30 2016-02-23 New York University Methods for screening to identify therapeutic agents for Alzheimer's disease and use thereof
EP2533051A1 (en) * 2011-06-06 2012-12-12 Centogene GmbH Method for the diagnosis of Gaucher's disease
WO2013018091A1 (en) * 2011-08-04 2013-02-07 Ramot At Tel-Aviv Universitiy Ltd. Particles for the treatment of neurodegenerative diseases
CN103120696A (zh) * 2011-11-18 2013-05-29 复旦大学 羊角衣酸在制备抗肿瘤药物中的应用
CN103120697B (zh) * 2011-11-18 2015-10-07 复旦大学 鳞片酸在制备抗肿瘤药物中的应用
CN104069263A (zh) * 2013-03-27 2014-10-01 中国科学院上海药物研究所 一种用于治疗阿尔茨海默病的制剂及其制备方法
EP2962687B1 (en) * 2013-04-02 2019-06-05 The Doshisha Tau aggregation inhibitor
CN105796579A (zh) * 2014-12-31 2016-07-27 中国科学院兰州化学物理研究所 抗老年性脑痴呆药物
WO2017096049A1 (en) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Materials for cathepsin b enhancement and methods of use
JP6940515B2 (ja) * 2016-03-25 2021-09-29 ジェンザイム・コーポレーション タンパク質症のバイオマーカーおよびその使用
RU2715703C1 (ru) * 2016-03-28 2020-03-03 Сайньюрекс Интернэшнл (Тайвань) Корп. Композиции, содержащие дубильные кислоты и их применение
CN105748460B (zh) * 2016-04-07 2018-11-02 大连医科大学附属第二医院 一种治疗老年痴呆的药物
ES2650175B1 (es) * 2016-04-15 2019-02-04 Servicio Andaluz De Salud Tratamiento de enfermedades neurodegenerativas
US10064833B2 (en) 2016-08-04 2018-09-04 Syneurx International (Taiwan) Corp. Compositions containing benzoate compound and tannic acid for treating central nervous system disorders
CN108143738A (zh) * 2016-12-02 2018-06-12 中国科学院大连化学物理研究所 一种治疗阿尔茨海默症的药物组合物及其制备和应用
CN107823198A (zh) * 2017-11-16 2018-03-23 黑龙江葆纳生物科技有限责任公司 北美圣草素在制备治疗阿尔茨海默病药物中的应用
CA3082916A1 (en) * 2017-12-07 2019-06-13 Guochuan Emil Tsai Improved enrichment methods for preparing tannic acid compositions
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
US11766423B2 (en) 2018-03-01 2023-09-26 The Johns Hopkins University 2,6-dimethoxy-4-(5-phenyl-4-thiophene-2-yl-1H-imidazol-2-yl)-phenol (DPTIP) a small molecule inhibitor of neutral sphingomyelinase 2 (nSMase-2) for the treatment of neurodegenerative and oncologic diseases
WO2020144753A1 (ja) * 2019-01-09 2020-07-16 公立大学法人大阪 神経変性疾患の予防又は治療薬
KR102102868B1 (ko) * 2019-05-14 2020-04-23 주식회사 노브메타헬스 고시페틴(Gossypetin)을 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
US11154531B2 (en) 2020-02-08 2021-10-26 Syneurx International (Taiwan) Corp. Compounds and pharmaceutical uses thereof
US10993958B1 (en) 2020-03-16 2021-05-04 William B. Coe Aldehyde functional monoterpenoids for the treatment of coronavirus infection
WO2021188575A1 (en) * 2020-03-16 2021-09-23 Coe William B Dietary supplement comprising aldehyde functional monoterpenoids
AU2021260663A1 (en) 2020-04-23 2022-11-10 Syneurx International (Taiwan) Corp. Compounds and pharmaceutical uses thereof
WO2022104011A1 (en) * 2020-11-12 2022-05-19 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
CN112870250B (zh) * 2021-01-21 2022-08-12 广东盛普生命科技有限公司 防治器官纤维化的组合物及其应用与制剂
CN112704680B (zh) * 2021-01-21 2022-08-02 广东盛普生命科技有限公司 预防和/或治疗器官纤维化的组合物及其应用与制剂
WO2024026390A2 (en) * 2022-07-28 2024-02-01 Wylder Nation Foundation Compositions and methods for diagnosing, treating, and preventing lysosomal storage diseases
KR20240023004A (ko) * 2022-08-12 2024-02-20 포항공과대학교 산학협력단 고시페틴을 포함하는 지방간 개선용 조성물
CN115417789B (zh) * 2022-09-03 2023-08-04 郑州大学 一种治疗帕金森氏病的化合物、其制备方法以及复方药物组合物和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
CA2523808A1 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
MX2007015602A (es) * 2005-06-08 2008-02-21 Amicus Therapeutics Inc Tratamiento de trastornos del sistema nervioso central asociados con mutaciones en genes que codifican las enzimas lisosomicas.
WO2007003941A1 (en) * 2005-07-06 2007-01-11 Cambridge Enterprise Limited Modulation of autophagy by calpain inhibition
MX2007006175A (es) * 2006-05-24 2009-02-16 Amicus Therapeutics Inc Sal de tartrato de isofagomina y metodos de uso.
JP5303458B2 (ja) * 2006-06-23 2013-10-02 アミークス セラピューティックス インコーポレイテッド β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法
WO2008031831A2 (en) * 2006-09-12 2008-03-20 Neurosearch A/S Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein

Similar Documents

Publication Publication Date Title
JP2015127343A5 (enExample)
JP2017008120A5 (enExample)
MA49402A (fr) Polynucléotides aadc pour le traitement de la maladie de parkinson
JP2014235432A5 (enExample)
JP2015528502A5 (enExample)
JP2017509667A5 (enExample)
JP2016535100A5 (enExample)
JP2018525542A5 (enExample)
IL263188B (en) Treatment for Parkinson's disease
JP2016102092A5 (enExample)
JP2017538836A5 (enExample)
MA45552A (fr) Compositions destinées au traitement de l'amylose
EP3373922A4 (en) COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA
PL3413870T3 (pl) Igmezyna do zastosowania do leczenia choroby alzheimera
JP2017019744A5 (enExample)
PL3352742T3 (pl) Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona
EP3634979A4 (en) COMPOSITIONS AND METHODS OF TREATING ALZHEIMER'S MORBUS
EP3601570A4 (en) METHOD FOR TREATMENT OF ALZHEIMER'S MORBUS
IL257802A (en) Preparations and methods for the treatment of Parkinson's disease
IL249428A0 (en) A polymorphic form of n-[2-(6 fluoro-lh-indol-3-yl)ethyl]-3-(2, 2, 3, 3-tetrafluoropropoxy)benzylamine hydrochloride for the treatment of Alzheimer's
MA40065A (fr) N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson
JP2017181387A5 (enExample)
EP3426803A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF MORBUS PARKINSON
HK40022834B (zh) 治疗阿尔茨海默病的组合物和方法
HK40024508A (en) Compositions and methods for treating alzheimer's disease